



Notification 6253

Implementation Date
7/6/23

Category
Drugs and Biologicals

Topic
Louisiana Medicaid - Frequency limitation for ocrelizumab, 1 mg

What is changing?

We limit reimbursement of charges for ocrelizumab, 1 mg, to the following:

- Second dose must be at least 2 weeks after initial dose
- Subsequent doses must be at least 6 months after the second dose and thereafter

Market
US

Language
English

Impacted Products

- Medicaid – Louisiana

Why is Humana making this change?

According to the FDA-approved package insert and prescribing information and pharmaceutical compendia, ocrelizumab, 1 mg, is limited to the frequencies listed above.